<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01316549</url>
  </required_header>
  <id_info>
    <org_study_id>P0037192</org_study_id>
    <secondary_id>10081</secondary_id>
    <nct_id>NCT01316549</nct_id>
  </id_info>
  <brief_title>Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation</brief_title>
  <acronym>HCT</acronym>
  <official_title>Population Pharmacokinetics of Fludarabine in Pediatric Patients Undergoing Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fludarabine is a chemotherapy drug used extensively in bone marrow transplantation. The goal&#xD;
      of this study is to determine what causes some children to have different drug concentrations&#xD;
      of fludarabine in their bodies and if drug levels are related to whether or not a child&#xD;
      experiences severe side-effects during their bone marrow transplant. The hypothesis is that&#xD;
      clinical and genetic factors cause changes in fludarabine drug levels in pediatric bone&#xD;
      marrow transplant patients and that high levels may cause severe side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fludarabine is a nucleoside analog with potent antitumor and immunosuppressive properties&#xD;
      used in conditioning regimens of pediatric allogeneic hematopoietic cell transplantation&#xD;
      (alloHCT) to promote stem cell engraftment.&#xD;
&#xD;
      This is a single-center, pharmacokinetic-pharmacodynamic (PK-PD) study investigating the&#xD;
      clinical pharmacology of fludarabine in 45 children undergoing alloHCT at University of&#xD;
      California, San Francisco Benioff Children's Hospital.&#xD;
&#xD;
      Patients would receive fludarabine regardless of whether or not they decide to consent to PK&#xD;
      sampling.&#xD;
&#xD;
      Fludarabine doses will not be adjusted based on PK data.&#xD;
&#xD;
      We will apply the combination of a D-optimality-based limited sampling strategy and&#xD;
      population PK methodologies to determine specific factors influencing fludarabine exposure in&#xD;
      pediatric alloHCT recipients and identify exposure-response relationships.&#xD;
&#xD;
      Subjects will undergo PK sampling of plasma (f-ara-a) and intracellular (f-ara-ATP) drug&#xD;
      concentrations over the duration of fludarabine therapy (3 to 5 days).&#xD;
&#xD;
      To evaluate sources of variability impacting fludarabine exposure clinical data will be&#xD;
      obtained from the patient's medical chart on each day of PK sampling.&#xD;
&#xD;
      A single blood draw for the collection of DNA and genotyping of single nucleotide&#xD;
      polymorphisms of genes involved in fludarabine activation, transport or elimination will&#xD;
      occur in all patients.&#xD;
&#xD;
      To assess exposure-response relationships neutrophil engraftment, treatment-related toxicity,&#xD;
      and survival data will be collected through day 100 post-transplant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2011</start_date>
  <completion_date type="Actual">April 30, 2016</completion_date>
  <primary_completion_date type="Actual">April 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of fludarabine for HCT in pediatric patients.</measure>
    <time_frame>2hours post start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of fludarabine for HCT in pediatric patients.</measure>
    <time_frame>3hours post start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of fludarabine for HCT in pediatric patients.</measure>
    <time_frame>6hours post start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Analysis of the Area under the Plasma Concentration versus Time Curve (AUC) of fludarabine for HCT in pediatric patients.</measure>
    <time_frame>24hours post start of infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event free survival according to the AUC of fludarabine</measure>
    <time_frame>1month post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival according to the AUC of fludarabine</measure>
    <time_frame>3months post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival according to the AUC of fludarabine</measure>
    <time_frame>1 year post transplant</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">67</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Nonmalignant Diseases</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Hemoglobinopathies</condition>
  <condition>Genetic Inborn Errors of Metabolism</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Thalassemia</condition>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Inpatient Pediatric Bone Marrow Transplant Recipients</arm_group_label>
    <description>All patients enrolled in this study will be located on the inpatient pediatric bone marrow transplant unit at University of California, San Francisco Benioff Children's Hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given as injection</description>
    <arm_group_label>Inpatient Pediatric Bone Marrow Transplant Recipients</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, DNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for the proposed study includes children 0-17 years of age undergoing&#xD;
        alloHCT for the treatment of malignant and nonmalignant disorders.&#xD;
&#xD;
        Patients receiving fludarabine over 3 to 5 days are eligible to participate.&#xD;
&#xD;
        All patients enrolled in this study will undergo PK sampling on the inpatient pediatric BMT&#xD;
        unit at UCSF Benioff Children's Hospital. The proposed research will not study any patients&#xD;
        receiving fludarabine in a clinic or any other out-patient setting.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 0-17 years of age&#xD;
&#xD;
          -  Undergoing alloHCT for the treatment of malignant or nonmalignant disorder&#xD;
&#xD;
          -  Receiving fludarabine-based preparative regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any child 7-17 years of age unwilling to provide assent&#xD;
&#xD;
          -  Parent or guardian unwilling to provide written consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janel R Long-Boyle, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2011</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fludarabine</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pediatric</keyword>
  <keyword>allogeneic</keyword>
  <keyword>hematopoietic cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

